Opinion|Videos|June 20, 2024
Changes in Presentation of Spasticity Over Time
The expert panel examines the evolution of moderate to severe spasticity following injury or insult, focusing on alterations in joint mobility, changes in range of motion from early to later stages, and other progressive manifestations of the condition.
Advertisement
Episodes in this series
- How does clinical presentation of moderate or severe spasticity change post-injury/insult (changes in joint movement, range of motion early vs later, etc.)?
Advertisement
Related to this article
An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.
The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.
Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.
Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.
Interim phase 1b data showed cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.
Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.
Here's some of what is coming soon to NeurologyLive® this week.
Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention
2
FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy
3
Identifying the Biggest Neuromuscular Advocacy Challenges for 2027: Paul Melmeyer, MPP
4
Understanding the Role of TAPS Therapy in Essential Tremor Management: Stuart H. Isaacson, MD, FAAN
5